Meeting
2013 ASCO Annual Meeting
Discordant ER, PR, and HER2 status between primary and metastatic breast cancer as prognostic factor.
Authors
Hee-Chul Shin
Chung-Ang University Hospital, Seoul, South Korea
Hee-Chul Shin , Wonshik Han , Hyeong-Gon Moon , Seock-Ah Im , Woo Kyung Moon , In-Ae Park , Sung Jun Park , Dong Young Noh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1039)
DOI
10.1200/jco.2013.31.15_suppl.1039
Abstract #
1039
Poster Bd #
18F
Abstract Disclosures
Similar Posters
Poster
2011 Breast Cancer Symposium
Factors associated with mortality after breast cancer metastasis.
First Author: S. Y. Jung
Poster
2022 ASCO Annual Meeting
ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC).
First Author: Qiang Zhang
Poster
2017 ASCO Annual Meeting
A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer.
First Author: William Jeffery Edenfield
Poster
2014 Breast Cancer Symposium
Does expression of estrogen receptor, progesterone receptor, and HER2 in atypical breast lesions predict a subsequent clinically significant event?
First Author: Judy Angela Tjoe